

DEC 05 2007

Attorney Docket No: MBP-005XX
Inventor(s): Kerstin Krieglstein
Application No. 09/786,435
TC Art Unit: 1645/Examiner: Vanessa L. Ford
OA Date: 09/05/07/Resp. Date: 12/05/07

AMENDMENT TO THE CLAIMS

1. (Previously Presented) A method for treating damaged neurons in a patient, said damaged neurons caused by a cerebral disorder, said method comprising the steps of:

providing a patient having damaged neurons, said damaged neurons caused by a cerebral disorder; and

administering to said patient a therapeutically effective amount of a compound that inhibits the biological activity of transforming growth factor- β 1 (TGF- β 1), transforming growth factor- β 2 (TGF- β 2) and/or transforming growth factor- β 3 (TGF- β 3) on damaged neurons in a cerebral disorder, thereby treating said damaged neurons in said patient by preventing neuronal apoptosis.

2-13. (Cancelled)

14. (Previously Presented) The method of claim 1, wherein said compound is selected from the group consisting of an inhibitor of TGF- β 1, TGF- β 2 and/or TGF- β 3; an antagonist to TGF- β 1, TGF- β 2 and/or TGF- β 3; and a composition altering TGF- β 1, TGF- β 2 and/or TGF- β 3.

15. (Previously Presented) The method of claim 14, wherein said compound is selected from the group consisting of an antibody directed to TGF- β 1, TGF- β 2 and/or TGF- β 3; and a composition having a binding site of a TGF- β 1, TGF- β 2 and/or TGF- β 3 receptor.

Attorney Docket No: MBP-005XX
Inventor(s): Kerstin Krieglstein
Application No. 09/786,435
TC Art Unit: 1645/Examiner: Vanessa L. Ford
OA Date: 09/05/07/Resp. Date: 12/05/07

16. (Currently Amended) The method of claim 1, wherein said method further comprises treating said patient with a ~~second~~ compound for disintegrating blood clots.

17. (Currently Amended) The method of claim 16, wherein said compound for disintegrating blood clots~~second compound~~ is selected from the group consisting of urokinase, thrombin, and tissue plasminogen activator.

18. (Currently Amended) The method of claim 1 or 17, wherein said compound that inhibits the biological activity of TGF- β 1 or said compound for disintegrating blood clots~~second compound~~ is administered intravenously, orally or intracerebrally.